Solid Tumor

Hutchison China MediTech (NASDAQ: HCM) has initiated a Phase 1b/2 study of surufatinib combined with BeiGene Ltd's (NASDAQ: BGNE) tislelizumab in patients with advanced solid tumors in the U.S. and Europe. The open-label study will evaluate the safety, tolerability,...

Enlivex Therapeutics Ltd (NASDAQ: ENLV) and Yale Cancer Center announced a research collaboration to assess the potential of Allocetra to enhance the activity of checkpoint inhibitors in solid tumors. Allocetra is a macrophage-reprogramming immunotherapy product, a potential...

Rubius Therapeutics Inc (NASDAQ: RUBY) stock is trading after reporting initial data from its ongoing Phase 1/2 trial of RTX-240 in patients with advanced solid tumors. Initial efficacy results showed a confirmed partial response (PR) with a 54% reduction in the target lesions...

Surface Oncology Inc (NASDAQ: SURF) has entered into a clinical trial collaboration with Merck & Co (NYSE: MRK) to evaluate Surface's SRF388 with the latter's Keytruda (pembrolizumab). This combination will be studied as a component of the Phase 1...